Wagner Wealth Management LLC Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Wagner Wealth Management LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 10.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,924 shares of the company’s stock after selling 438 shares during the quarter. Wagner Wealth Management LLC’s holdings in Johnson & Johnson were worth $568,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. AMF Tjanstepension AB grew its position in Johnson & Johnson by 14.2% in the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after acquiring an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC acquired a new position in shares of Johnson & Johnson in the third quarter valued at approximately $209,000. Wealth Group Ltd. purchased a new stake in Johnson & Johnson during the 3rd quarter worth approximately $213,000. Wedge Capital Management L L P NC lifted its holdings in Johnson & Johnson by 2.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 4,039 shares of the company’s stock worth $655,000 after buying an additional 86 shares in the last quarter. Finally, Creative Planning boosted its position in Johnson & Johnson by 4.3% in the 3rd quarter. Creative Planning now owns 988,403 shares of the company’s stock valued at $160,181,000 after buying an additional 41,082 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on JNJ. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Wolfe Research started coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target on the stock. Bank of America lowered their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Raymond James reduced their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Finally, Stifel Nicolaus lowered their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Stock Down 0.6 %

Johnson & Johnson stock opened at $155.23 on Thursday. The stock has a 50-day simple moving average of $147.48 and a 200-day simple moving average of $156.01. The company has a market capitalization of $373.73 billion, a P/E ratio of 23.34, a PEG ratio of 2.46 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.29 earnings per share. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.20%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.